Blinatumomab for treating acute lymphoblastic leukaemia in remission with minimal residual disease activity

Technology appraisal guidance
Reference number: TA589
Published: 24 July 2019

History

Expected publication

Equality Impact Assessment (Guidance development) (PDF 157 KB)

Published:

24 July 2019

Final draft guidance

Final draft guidance
Final appraisal document (PDF 335 KB)

Published:

19 June 2019
Committee papers (PDF 4.99 MB)

Published:

19 June 2019

Draft guidance

Draft guidance
Appraisal consultation document (PDF 281 KB)

Published:

06 March 2019
Committee papers (PDF 11.19 MB)

Published:

06 March 2019
Public committee slides (PDF 475 KB)

Published:

06 March 2019

Invitation to participate

Final scope (PDF 234 KB)

Published:

06 June 2017
Final matrix (PDF 261 KB)

Published:

06 June 2017